How it works

Placement by design. Precise, structured pigment positioning in the dermal layer, aligned with skin micro-architecture and physiology. Compatibility focus — expected to reduce complications at placement.

Everyday stability. In daily life the system is inert: tattoo/PMU behaves as usual.

Gentle removal. On demand — painless, as there is no impact on nerve endings. Controlled external physical activation with professional-grade equipment only.

Design flexibility. Fragmentary edits (remove selected areas) with re-inking a new design over cleared zones.

Use-cases

PMU / permanent makeup

Refresh and corrections; reduces fear of irreversibility. Fewer complications expected at both placement and removal.

Tattoo redesign

Fragmentary removal of selected areas and re-inking over cleared zones.

Vitiligo (conceptual)

Edge tone adaptation; requires dedicated research.

Research streams

Materials, optics, metrics, ex vivo and 3D skin models.

Who it touches

People & communities. Tattoo/PMU users, aesthetic clients, people wary of “irreversibility”, youth aiming at future military or public service.

Professional groups. Tattoo artists and studios, PMU specialists, aesthetic clinics, dermatologists, regulatory and training centers.

Public sector & health systems. Service quality and safety; reduced complications at placement and removal.

Education & science. Universities, student teams, labs in materials/dermatology/optics.

Markets & money — why this is big

  • Hundreds of millions of tattoo/PMU wearers; double-digit growth of tattoo removal services.
  • New service category: “on-demand reversibility” → repeat visits, subscriptions to corrections and refresh.
  • Wide value chain: materials, pigment systems, disposables, training, equipment, service plans.
  • You can estimate the revenue potential yourself using AI and open data.

Our niche on the scientific map

The “controlled reversibility” approach emerges at the intersection of dermatology, biotechnology, and materials science. We leverage recent advances and combine them in a previously undescribed way.

Several inventive steps create novelty and a sizable market space — opening a pathway to a new standard of controlled reversibility and a broad field for research and development.

Benefits

Control. On-demand removal reduces the “fear of irreversibility” and builds confidence. Fragmentary edits with new design on cleared zones.

Safety-first. Tissue compatibility and gentle activation; expected to reduce complications at placement and removal.

Precision. Targeted work with potential for “pixel-level” execution.

Workflow. From one-off to lifecycle: placement → corrections/refresh → redesign.

What this brings at global scale

  • Fewer complications and unpredictable outcomes — at both placement and removal.
  • Toward a new standard of tattoo placement & removal via visual metrics and assessment protocols.
  • New educational tracks and interdisciplinary research.
  • A market of repeat services and higher quality of service.

Origin story

This is a family invention. The father-inventor is against getting tattoos; the son supports tattoos. After many debates, a challenge emerged — design a technology for placement and painless removal on a person’s request. Two viewpoints, two generations — one solution. We’ve spent thousands of hours searching for it.

That’s how a new, elegant technology appeared: long-lasting tattoos that can be removed on demand without harm. We already have a solid foundation — the idea, patent protection, and a research roadmap.

Our take on this technology:

  • it is elegant as an inventive solution;
  • it will require up to 3 years of R&D;
  • first demo on lab-grown human skin is possible in 12–18 months;
  • funding needed for first demo — €1.43–1.62M;
  • to reach implementation level — additional €2.65–3.15M.

How to help:

We self-fund this project now — it’s hard. You can support research, specific studies, targeted help to inventors, outreach and information support.

We also welcome unexpected ideas and approaches.

Sincerely, Andrii & Kyrylo.

Partners — from idea to scale

Stepwise: lab safety & methods → skin models → pigment systems & SOPs → regulators → NDA pilots → scale-up. Technical details available under NDA only.

Stage 0 — Safety & methods

  • Materials & compatibility: screening of skin-compatible options: photostability, toxicology (in-vitro panels), cellular interaction, correct dermal positioning.
  • Optics & metrics: unified before/after capture, color metrics (e.g., ΔE*), collaboration with measurement labs.
  • Ethics & quality: SOPs, risk management, GLP compliance.

Stage 1 — Skin models & visual standards

  • Ex vivo / 3D skin: academic and commercial models to develop placement/removal approaches.
  • Optical rigs: photometry/spectrometry; calibration for comparable results.
  • Documentation: independent centers for standardized before/after photography and blind assessment.

Stage 2 — Pigment systems & disposables

  • Pigments: skin-tone/PMU solutions with required stability and purity; batch traceability.
  • Disposables & tools: design and packaging without public parameter disclosure; IFU.
  • SOPs: clear placement/assessment/follow-up methods without publishing ranges or UI.

Stage 3 — Regulatory tracks (EU / US)

  • EU: EC 1223/2009, REACH; safety assessment, dossier, cosmetovigilance.
  • US: FDA MoCRA 2022; quality, labeling, notifications.
  • Documentation: supplier audits, compliance roadmap, change control.

Stage 4 — NDA pilots (clinics / studios)

  • Aesthetic/derm clinics: pilot protocols, safety, photo registries.
  • Tattoo/PMU studios: certified sites with standardized operating procedures.
  • Independent verification: external expert panels on quality metrics.

Stage 5 — Training, certification, service safety

  • Training centers: curricula for artists and clinics, exams and competency control.
  • Site certification: checklists, audits, periodic renewals.
  • Client communication: informed consent, aftercare, complaint & incident handling.

IP & publications policy. Background IP remains with the owner. Jointly created Foreground IP is co-owned with agreed filing/licensing. Publications follow patent filings and a joint plan. IP policy is fixed in NDA + Term Sheet before work starts.

Materials are shared under NDA with qualified organizations and teams (academic/clinical units, certified labs, industry partners). We do not publicly disclose parameters, ranges, formulas, UI, or step-by-step protocols.

FAQ

Why don’t you disclose parameters/formulas?

To preserve patent rights and avoid unsafe DIY. Details available under NDA until the patent application is published. After publication, the claims will be public.

Who owns IP in joint research?

Background IP stays with the owner. Foreground IP created in the project is co-owned with named co-inventors and an agreed process for filing/costs/licensing.

If we join now, what can we expect?

Contract-defined economic rights: an option to license in your field/territory upon meeting pilot KPIs; a share in joint IP (if contributing to Foreground IP); and an agreed monetization model (royalties/fees or preferred terms). Also priority access to results and internal use rights per agreement.

What is an NDA?

A Non-Disclosure Agreement signed before exchanging sensitive info. It grants access to confidential materials and prohibits disclosure or use outside the agreed purpose. Usually 2–4 pages; time-limited; covers tech data, samples, and reports.

What does “painless removal” mean?

No impact on nerve endings → comfortable for the client (professional-grade equipment only).

Will this cut tattoo-artist jobs?

We advocate preserving traditional craft and jobs. No mass deployment of medical robots is planned; their share is capped at ~10%.

Updates

Q4 2025
PCT application under review

Technical details available under NDA.

Q1 2026
—

Future updates.

Q2 2026
—

Future updates.

Q3 2026
—

Future updates.

Q4 2026
—

Future updates.